143 related articles for article (PubMed ID: 11690547)
1. Gene therapy for bladder cancer using adenoviral vector.
Wada Y; Gotoh A; Shirakawa T; Hamada K; Kamidono S
Mol Urol; 2001; 5(2):47-52. PubMed ID: 11690547
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
[TBL] [Abstract][Full Text] [Related]
3. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer.
Eastham JA; Hall SJ; Sehgal I; Wang J; Timme TL; Yang G; Connell-Crowley L; Elledge SJ; Zhang WW; Harper JW
Cancer Res; 1995 Nov; 55(22):5151-5. PubMed ID: 7585563
[TBL] [Abstract][Full Text] [Related]
4. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model.
Miyake H; Hara I; Hara S; Arakawa S; Kamidono S
Urology; 2000 Aug; 56(2):332-6. PubMed ID: 10925118
[TBL] [Abstract][Full Text] [Related]
5. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer.
Hamada K; Alemany R; Zhang WW; Hittelman WN; Lotan R; Roth JA; Mitchell MF
Cancer Res; 1996 Jul; 56(13):3047-54. PubMed ID: 8674061
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer.
Miyake H; Hanada N; Nakamura H; Kagawa S; Fujiwara T; Hara I; Eto H; Gohji K; Arakawa S; Kamidono S; Saya H
Oncogene; 1998 Feb; 16(7):933-43. PubMed ID: 9484785
[TBL] [Abstract][Full Text] [Related]
8. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus.
Liu TJ; Zhang WW; Taylor DL; Roth JA; Goepfert H; Clayman GL
Cancer Res; 1994 Jul; 54(14):3662-7. PubMed ID: 8033080
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Parker LP; Wolf JK; Price JE
Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
[TBL] [Abstract][Full Text] [Related]
10. In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer.
Baek JH; Agarwal ML; Tubbs RR; Vladisavljevic A; Tomita H; Bukowski RM; Milsom JW; Kim JM; Kwak JY
J Korean Med Sci; 2004 Dec; 19(6):834-41. PubMed ID: 15608394
[TBL] [Abstract][Full Text] [Related]
11. p53 Mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells.
Irie A; Uchida T; Ishida H; Matsumoto K; Iwamura M; Baba S
Mol Urol; 2001; 5(2):53-8. PubMed ID: 11690548
[TBL] [Abstract][Full Text] [Related]
12. Preclinical study of adenoviral p53 gene therapy for esophageal cancer.
Shimada H; Shimizu T; Ochiai T; Liu TL; Sashiyama H; Nakamura A; Matsubara H; Gunji Y; Kobayashi S; Tagawa M; Sakiyama S; Hiwasa T
Surg Today; 2001; 31(7):597-604. PubMed ID: 11495154
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers.
Gotoh A; Kao C; Ko SC; Hamada K; Liu TJ; Chung LW
J Urol; 1997 Aug; 158(2):636-41. PubMed ID: 9224383
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for bladder cancer.
Pagliaro LC
World J Urol; 2000 Apr; 18(2):148-51. PubMed ID: 10854151
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin.
Pagliaro LC; Keyhani A; Liu B; Perrotte P; Wilson D; Dinney CP
Urol Oncol; 2003; 21(6):456-62. PubMed ID: 14693272
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral p53 gene therapy promotes heat-induced apoptosis in a nasopharyngeal carcinoma cell line.
Qi V; Weinrib L; Ma N; Li JH; Klamut H; Liu FF
Int J Hyperthermia; 2001; 17(1):38-47. PubMed ID: 11212879
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma.
Weinrib L; Li JH; Donovan J; Huang D; Liu FF
Cancer Gene Ther; 2001 May; 8(5):352-60. PubMed ID: 11477455
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.
Komata T; Kondo Y; Koga S; Ko SC; Chung LW; Kondo S
Gene Ther; 2000 Dec; 7(24):2071-9. PubMed ID: 11223987
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck.
Liu TJ; el-Naggar AK; McDonnell TJ; Steck KD; Wang M; Taylor DL; Clayman GL
Cancer Res; 1995 Jul; 55(14):3117-22. PubMed ID: 7606733
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.
Yamanaka K; Gleave ME; Hara I; Muramaki M; Miyake H
Mol Cancer Ther; 2005 Feb; 4(2):187-95. PubMed ID: 15713890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
